"摘要赏析"标签列表

[APASL2013]中国临床实践中恩替卡韦与其他标准疗法治疗核苷（酸）初治慢性乙肝患者长达4年的比较2013-06-07

[APASL2013]Vaccine Therapy in Hepatitis B Carriers: A Randomized Double Blind Clinical Trial2013-06-07

[APASL2013]乙肝携带者疫苗疗法：一项随机双盲临床试验2013-06-07

[APASL2013]Allogeneic Bone Marrow Mesenchymal Stem Cells Improves Outcomes of HBV Related Acute-on-Chronic Liver Failure2013-06-07

[APASL2013]异基因骨髓间充质干细胞改善HBV相关慢加急性肝功能衰竭预后2013-06-07

[APASL2013]ABT-450/r，ABT-267，ABT-333+/-利巴韦林的无干扰素疗法在慢性HCV基因型1b型患者获得高SVR12率2013-06-07

[APASL2013]N-CORE: Sustained Virological Response Rates with Peginterferon Alfa-2a/Ribavirin (PegIFN-alfa/RBV) in HCV G2 or 3 Patients without Rapid Virological Response2013-06-07

[APASL2013]Sofosbuvir+利巴韦林口服治疗经治基因型2/3型HCV感染患者12或16周：FUSION试验2013-06-07

[APASL2013]Could Vitamin D Supplementation Improve Response to Antiviral Treatment for Hepatitis C Virus Genotype 4?2013-06-07

[APASL2013]Responses and Adverse Effects of Triple Therapy with Telaprevir， PegIFN and Ribavirin in Patients with Hepatitis C Virus Infection2013-06-07

[APASL2013]无干扰素，无利巴韦林治疗方案Daclatasvir，Asunaprevir和BMS-791325治疗慢性HCV基因型1型感染初治患者2013-06-07

[APASL2013]N-CORE：聚乙二醇干扰素Alfa-2a/利巴韦林（PegIFN-alfa/RBV）治疗无快速病毒学应答的HCV G2或3型患者的持续病毒学应答率2013-06-07

[APASL2013]抗病毒治疗作为HCV相关肝硬化肝细胞癌（HCC）复发的二级预防：一项病例对照研究2013-06-07

[APASL2013]由利托那韦增强的danoprevir（DNVr）联合PegIFNα-2a干扰素（40KD）/利巴韦林（P/R）治疗HCV基因型（G）1b感染先前部分/无应答者的SVR率高达91％2013-06-07

[APASL2013]Alisporivir（ALV）+利巴韦林（RBV）（+/-干扰素）治疗HCV G2/3初治患者24周可获得高HCV持续清除率：最终SVR242013-06-07

[APASL2013]A Novel Method for Non-Invasive Diagnosis of Hepatitis C Virus Using Electromagnetic Signal Detection: A Multicenter International Study2013-06-07

[APASL2013]48 Weeks of Therapy Might Not Be Needed for the Patients with HCV Genotype 2 without RVR like EASL Guideline2013-06-07

[APASL2013]无RVR的HCV基因型2型患者也许并不像EASL指南所建议的那样需要48周治疗2013-06-07

[APASL2013]All Oral Therapy with Sofosbuvir+Ribavirin for 12 or 16 Weeks in Treatment Experienced Genotype 2/3 HCV-Infected Patients: The FUSION Trial2013-06-07

[APASL2013]An Interferon-free， Ribavirin-free Regimen of Daclatasvir， Asunaprevir， and BMS-791325 in Treatment-Naive Patients with Genotype 1 Chronic Hepatitis C Virus Infection2013-06-07